CymaBay Therapeutics, Inc.

NASDAQ: CBAYHealthcare / Biotechnology / USA
6.28-0.4700-6.96%Vol 1 408 6641Y Perf -51.95%
Jun 14th, 2019 16:00
BID6.22 ASK6.35
Open6.69 Previous Close6.75
Pre-Market6.76 After-Trading6.28
 0.01 0.15%  - -%
Target Price
21.00 
Analyst Rating
Strong Buy 1.30
Potencial %
234.40 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-20/20 
Value Ranking
★★ —    -
Insiders Value % 3/6/12M
-/-81/-58 
Growth Ranking
★★★ —    -
Insiders Shares Cnt. % 3/6/12M
-/-77/-60 
Income Ranking
 —    -
Market Cap (mil)431 
Earnings Rating
Sell
Price Range Ratio 52wk %
14.34 
Earnings Date
8th Aug 2019

Today's Price Range

6.246.80

52wk Range

4.8215.00

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Month
-51.58%
3 Months
-51.13%
6 Months
-27.48%
1 Year
-51.95%
3 Years
254.80%
5 Years
-21.40%

Name / TickerPriceChg.Chg.%
CBAY6.28-0.4700-6.96
AAPL192.74-1.4100-0.73
GOOG1 085.35-3.4200-0.31
MSFT132.450.13000.10
XOM74.35-0.3300-0.44
WFC45.590.30000.66
JNJ140.09-0.6200-0.44
FB181.333.86002.18
GE10.23-0.0800-0.78
JPM109.820.28000.26
Earnings HistoryEstimateReportedSurprise %
Q01 2019-0.34-0.37-8.82
Q04 2018-0.36-0.3211.11
Q03 2018-0.30-0.34-13.33
Q02 2018-0.25-0.30-20.00
Q01 2018-0.14-0.32-128.57
Q04 2017-0.17-0.1135.29
Q03 2017-0.19-0.21-10.53
Q02 2017-0.25-0.31-24.00
Earnings Per EndEstimateRevision %Trend
6/2019 QR-0.36-5.88Negative
9/2019 QR-0.370.00-
12/2019 FY-1.48-4.23Negative
12/2020 FY-1.58-3.95Negative
Next Report Date8th Aug 2019
Estimated EPS Next Report-0.36
Estimates Count8
EPS Growth Next 5 Years %-
Volume Overview
Volume1 408 664
Shares Outstanding (in ths.)68 694
Trades Count5 708
Dollar Volume8 116 229
Avg. Volume987 891
Avg. Weekly Volume5 845 245
Avg. Monthly Volume2 400 106
Avg. Quarterly Volume1 190 213
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (80.00 %)
7 (77.78 %)
7 (77.78 %)
Moderate Buy
1 (10.00 %)
1 (11.11 %)
1 (11.11 %)
Hold
1 (10.00 %)
1 (11.11 %)
1 (11.11 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingStrong Buy
1.30
Strong Buy
1.33
Strong Buy
1.33

CymaBay Therapeutics, Inc.

CymaBay Therapeutics Inc is a part of the healthcare sector based in the United States. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes and MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta.

CEO: Sujal Shah

Teplephone: +1 510 293-8800

Address: 7575 Gateway Boulevard, Newark 94560, CA, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

47%53%

Bearish Bullish

60%40%

Bearish Bullish

68%32%

News